Oligomeric Amyloid-beta
Oligomeric Amyloid-beta - Related Videos
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
0 Views •
Cited by 41 •
2015
Here, we present a protocol for direct stereotaxic brain infusion of amyloid-beta. This methodology provides an alternative in vivo mouse model to address the short-term effects of amyloid-beta on brain neurons.
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
0 Views •
Cited by 74 •
2010
One feature of Alzheimer's Disease is the elevation of Aβ1-42 peptide. Here we provide a protocol for preparing synthetic Aβ1-42 oligomers, which impairs hippocampal Long-Term Potentiation, a cellular correlate of memory. This procedure is useful for investigating mechanisms of Aβ-induced pathology and drug screening.
04:48
Fluorescence Fluctuation Spectroscopy to Study Protein Homo-Oligomerization
0 Views •
2025
This video demonstrates the technique of fluorescence fluctuation spectroscopy (FFS) to study protein homo-oligomerization. Fluorescently-labeled proteins in a sample are dimerized using an agent when studying protein oligomerization using FFS. Using a confocal microscope, as the proteins move in and out of the small observation volume, the analysis of the fluctuations in the brightness of the fluorescent molecules is performed to determine the oligomeric state of the proteins.
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
12:43
Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
0 Views •
Cited by 3 •
2016
Oligomerization of the ryanodine receptor, a homo-tetrameric ion channel mediating Ca2+ release from intracellular stores, is critical for skeletal and cardiac muscle contraction. Here, we present complementary in vivo and in vitro methods to detect protein self-association and determine homo-oligomer stoichiometry.
FAQs
These assemblies can interact with neuronal membranes and synaptic proteins, affecting the systems that support communication between brain cells. Their reported effects include altered signaling, disturbed calcium regulation, and impaired cellular homeostasis. Together, these changes provide a mechanistic link between amyloid-beta assembly states and synaptic dysfunction studied in Alzheimer’s disease research.
The assembly state matters because monomers, oligomers, and fibrils represent different forms of amyloid-beta during aggregation. Focusing specifically on oligomers helps researchers relate soluble assemblies to membrane and synaptic effects rather than attributing all biological findings to amyloid-beta generally. This distinction also supports more precise interpretation of pathology and treatment results.
Selective targeting is important because therapeutic strategies may need to recognize particular amyloid-beta assemblies rather than the entire range of peptide forms. Antibodies or other treatments directed toward oligomeric species can be evaluated for whether they address assemblies associated with altered signaling and cellular homeostasis. This approach may clarify which forms are most relevant to disease mechanisms.
Researchers study these assemblies as one part of the connection between amyloid-beta aggregation and neuronal dysfunction. Observing their interactions with neuronal membranes and synaptic proteins can help explain changes in signaling, calcium regulation, and cellular homeostasis. This mechanistic context supports broader efforts to understand how molecular assembly states may relate to Alzheimer’s disease pathology.
Research on oligomeric amyloid-beta supports efforts to identify biomarkers that reflect relevant amyloid-beta assembly states. Such markers could help investigators distinguish oligomer-related findings from observations involving monomers or fibrils. In medicine, this distinction is valuable for interpreting disease-associated changes and for assessing whether experimental treatments affect the peptide assemblies under study.
Separating oligomers from other amyloid-beta forms allows treatment studies to examine whether an antibody or another therapy acts on the intended assembly state. Researchers can then interpret outcomes in relation to the assemblies linked with membrane, synaptic, signaling, or calcium-regulation effects. This supports more focused assessment of therapeutic strategies in Alzheimer’s disease research.